DV
Dividend Vision

DRMA — Dermata Therapeutics Inc

Dermata Therapeutics Inc (DRMA)

Total return is -100.0% over the past 5 years, 186.3 points behind SPY at 86.3%. Its deepest 1-year drawdown was 83.3%.

Dermata Therapeutics develops and distributes over-the-counter dermatology products, including direct-to-consumer skincare items for skin renewal and acne treatment sold under the Tome brand in the United States. The company does not currently distribute dividends to shareholders. This security appeals primarily to investors seeking equity exposure to the specialty dermatology product sector rather than those focused on income generation.

DRMA key facts

Asset type
Stock
Asset class
Equity
Inception date
08/13/2021
Last close
$1.46
Market cap
$5,349,450
Average volume
416700.0
Beta
0.667
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.17